Document Type : Review Article


1 Department of Health Care Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, H-12, Islamabad, Pakistan

2 Applied Chemistry Department, College of Applied Science, University of Samarra, Samarra, Iraq

3 Department of Surgery, College of Medicine, Ibn Sina University of Medical and Pharmaceutical Sciences, Baghdad, Iraq

4 Department of Agronomy and Plant Breeding, Faculty of Agriculture and Natural Resources, University of Mohaghegh Ardabili, Ardabil, Iran

5 Faculty of Pharmacy, Cyprus International University, Lefkosa, Turkish Republic of Northern Cyprus, Lefkosa, Cyprus


MicroRNAs (miRNA) are a group of small non-coding RNAs that regulate gene expression at the RNA level. MicroRNAs have positive regulatory effects on protein translation processes and often induce their performance by binding to the 3'-UTR mRNA region. Also, microRNAs are involved in various cellular processes, including development, cell division, cell signaling, and cell growth, and generally play an effective role in the cell cycle and control of physiological processes and cell pathology. Several studies confirm that microRNAs play an important role in the initiation and progression of cancer, and many of them act as oncogenes and tumor suppressors. On the other hand, microRNAs are important stimulating factors that can act as biomarkers in the diagnosis and prognosis of various types of cancer, and in many cases, the occurrence of mutations in microRNAs and open-reading templates can lead to cancer. MicroRNAs also play an effective role in regulating gene expression. Biological studies have shown that about 30% of all genes and the majority of genetic pathways are regulated by microRNAs. In general, microRNAs and their target molecules are potential biological goals for primary screening, targeted treatment, and pharmaceutical resistance, and identifying them provides a clear prospect for a better understanding of the pathways leading to cancer.

Graphical Abstract

Comprehensive analysis of microRNA (miRNA) in cancer cells


Main Subjects

Selected author of this article by journal

Dr. Othman Rashid Al Samarrai
University of Samarra
Google Scholar

Open Access

This article is licensed under a CC BY License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit:


Publisher’s Note

CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.


Letters to Editor

Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 15%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.

CMBR Journal welcomes letters to the editor ([email protected], [email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.

[1] Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.

[2] Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.

[3] There is no limit to the number of words in a letter.

[4] Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.

[5] Anonymous letters will not be considered.

[6] Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments.

[7] Letters will be answered as soon as possible.

  1. López-Urrutia E, Bustamante Montes LP, Ladrón de Guevara Cervantes D, Pérez-Plasencia C, Campos-Parra AD (2019) Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. Frontiers in oncology 9): 669. doi:
  2. Amodio F, Caiazza M, Fimiani F, Calabrò P, Limongelli G (2021) MicroRNAs: From Junk RNA to Life Regulators and Their Role in Cardiovascular Disease. Cardiogenetics 11 (4): 230-254. doi:
  3. Ren B, Guan M-X, Zhou T, Cai X, Shan G (2022) Emerging functions of mitochondria-encoded noncoding RNAs. Trends in Genetics). doi:
  4. Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: Playing with fire. FEBS Letters 585 (13): 2087-2099. doi:
  5. Lundstrom K (2011) Micro-RNA in disease and gene therapy. Current Drug Discovery Technologies 8 (2): 76-86. doi:
  6. Wang W, Hao L-P, Song H, Chu X-Y, Wang R (2022) The potential roles of exosomal non-coding RNAs in hepatocellular carcinoma. Frontiers in Oncology 12): Article 790916. doi:
  7. Mirnezami AHF, Pickard K, Zhang L, Primrose JN, Packham G (2009) MicroRNAs: Key players in carcinogenesis and novel therapeutic targets. European Journal of Surgical Oncology (EJSO) 35 (4): 339-347. doi:
  8. Benetatos L, Vartholomatos G (2012) Deregulated microRNAs in multiple myeloma. Cancer 118 (4): 878-887. doi:
  9. Liu C-G, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, Dumitru CD, Shimizu M, Zupo S, Dono M (2004) An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proceedings of the National Academy of Sciences 101 (26): 9740-9744. doi:
  10. Hashemipour M, Boroumand H, Mollazadeh S, Tajiknia V, Nourollahzadeh Z, Rohani Borj M, Pourghadamyari H, Rahimian N, Hamblin MR, Mirzaei H (2021) Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers. Gynecologic Oncology 161 (1): 314-327. doi:
  11. Rahaman M, Mukherjee M, Bhattacharya S, Mukherjee B, Shukla PC, Dolai TK, Chakravorty N (2022) Exploring the crosstalk between long non-coding RNAs and microRNAs to unravel potential prognostic and therapeutic biomarkers in β-thalassemia. Molecular Biology Reports): 1-12. doi:
  12. Ramalingam H, Yheskel M, Patel V (2020) Modulation of polycystic kidney disease by non-coding RNAs. Cellular Signalling 71): 109548. doi:
  13. Gajek A, Gralewska P, Marczak A, Rogalska A (2021) Current implications of microRNAs in genome stability and stress responses of ovarian cancer. Cancers 13 (11): 2690. doi:
  14. Ghasabi M, Mansoori B, Mohammadi A, Duijf PH, Shomali N, Shirafkan N, Mokhtarzadeh A, Baradaran B (2019) MicroRNAs in cancer drug resistance: Basic evidence and clinical applications. Journal of cellular physiology 234 (3): 2152-2168. doi:
  15. Omar HA, El‐Serafi AT, Hersi F, Arafa ESA, Zaher DM, Madkour M, Arab HH, Tolba MF (2019) Immunomodulatory MicroRNAs in cancer: targeting immune checkpoints and the tumor microenvironment. The FEBS Journal 286 (18): 3540-3557. doi:
  16. Fazeli-Nasab B, Sayyed RZ, Sobhanizadeh A (2021) In Silico Molecular Docking Analysis of α-Pinene: An Antioxidant and Anticancer Drug Obtained from Myrtus communis. Int J Cancer Manag 14 (2): e89116. doi:
  17. Tokumaru Y, Asaoka M, Oshi M, Katsuta E, Yan L, Narayanan S, Sugito N, Matsuhashi N, Futamura M, Akao Y (2020) High expression of microRNA-143 is associated with favorable tumor immune microenvironment and better survival in estrogen receptor positive breast cancer. International journal of molecular sciences 21 (9): 3213. doi:
  18. Xing Y, Ruan G, Ni H, Qin H, Chen S, Gu X, Shang J, Zhou Y, Tao X, Zheng L (2021) Tumor immune microenvironment and its related miRNAs in tumor progression. Frontiers in Immunology 12): 624725. doi:
  19. Lai X, Eberhardt M, Schmitz U, Vera J (2019) Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer. Nucleic acids research 47 (15): 7753-7766. doi:
  20. Xie X, Pan J, Han X, Chen W (2019) Downregulation of microRNA-532-5p promotes the proliferation and invasion of bladder cancer cells through promotion of HMGB3/Wnt/β-catenin signaling. Chemico-Biological Interactions 300): 73-81. doi:
  21. Wong KY, Yu L, Chim CS (2011) DNA methylation of tumor suppressor miRNA genes: a lesson from the miR-34 family. Epigenomics 3 (1): 83-92. doi:
  22. Wang LQ, Chim CS (2015) DNA methylation of tumor-suppressor miRNA genes in chronic lymphocytic leukemia. Epigenomics 7 (3): 461-473. doi:
  23. Lewis B, Burge C (2005) Bartel DPJc. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets 120 (1): 15-20. doi:
  24. Li Z, Wong KY, Calin GA, Chng W-J, Chan GC-f, Chim CS (2019) Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. Clinical epigenetics 11 (1): 1-13. doi:
  25. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, Jones PA (2006) Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9 (6): 435-443. doi:
  26. Kanellopoulou C, Monticelli S (2008) A role for microRNAs in the development of the immune system and in the pathogenesis of cancer. Seminars in Cancer Biology 18 (2): 79-88. doi:
  27. Lan X, Ruminy P, Bohers E, Rainville V, Viennot M, Viailly P-J, Etancelin P, Tilly H, Mihailescu S, Bouclet F, Leprêtre S, Jardin F (2022) 5′ Rapid amplification of cDNA ends (5′RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia. Leukemia Research 123): 106952. doi:
  28. Babashah S, Soleimani M (2011) The oncogenic and tumour suppressive roles of microRNAs in cancer and apoptosis. European Journal of Cancer 47 (8): 1127-1137. doi:
  29. Bűssing I, Slack FJ (2008) a Großhans, Helge. let-7 microRNAs in development, stem cells and cancer. Trends in molecular medicine 14 (9): 400-409. doi:
  30. Cho WCS (2010) MicroRNAs in cancer — from research to therapy. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1805 (2): 209-217. doi:
  31. Cho WCS (2010) MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. The International Journal of Biochemistry & Cell Biology 42 (8): 1273-1281. doi:
  32. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ (2012) Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Critical Reviews in Oncology/Hematology 81 (2): 103-122. doi:
  33. Hanahan D, Weinberg Robert A (2011) Hallmarks of Cancer: The Next Generation. Cell 144 (5): 646-674. doi:
  34. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, Stephan C, Jung K (2010) MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urologic Oncology: Seminars and Original Investigations 28 (1): 4-13. doi:
  35. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: Novel regulators in the hallmarks of human cancer. Cancer Letters 285 (2): 116-126. doi:
  36. Nguyen D-D, Chang S (2017) Development of novel therapeutic agents by inhibition of oncogenic microRNAs. International journal of molecular sciences 19 (1): 65. doi:
  37. Wu K, He J, Pu W, Peng Y (2018) The Role of Exportin-5 in MicroRNA Biogenesis and Cancer. Genomics, Proteomics & Bioinformatics 16 (2): 120-126. doi:
  38. Miller BH, Wahlestedt C (2010) MicroRNA dysregulation in psychiatric disease. Brain Research 1338): 89-99. doi:
  39. Friedman RC, Farh KK-H, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome research 19 (1): 92-105. doi:
  40. Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R (2011) Diabetes mellitus, a microRNA-related disease? Translational Research 157 (4): 253-264. doi:
  41. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nature reviews cancer 6 (11): 857-866. doi:
  42. Jiang K, Zou H (2022) microRNA-20b-5p overexpression combing Pembrolizumab potentiates cancer cells to radiation therapy via repressing programmed death-ligand 1. Bioengineered 13 (1): 917-929. doi:
  43. Xiang Y, Lv D, Song T, Niu C, Wang Y (2022) Tumor suppressive role of microRNA-139-5p in bone marrow mesenchymal stem cells-derived extracellular vesicles in bladder cancer through regulation of the KIF3A/p21 axis. Cell Death & Disease 13 (7): 1-12. doi:
  44. Weng S, Lin D, Lai S, Tao H, Chen T, Peng M, Qiu S, Feng S (2022) Highly sensitive and reliable detection of microRNA for clinically disease surveillance using SERS biosensor integrated with catalytic hairpin assembly amplification technology. Biosensors and Bioelectronics 208): 114236. doi:
  45. Li C, Wang R, Wu A, Yuan T, Song K, Bai Y, Liu X (2022) SARS-COV-2 as potential microRNA sponge in COVID-19 patients. BMC Medical Genomics 15 (2): 1-10. doi:
  46. Kara G, Arun B, Calin GA, Ozpolat B (2022) miRacle of microRNA-Driven Cancer Nanotherapeutics. Cancers 14 (15): 3818. doi:
  47. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T (2006) Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell Lines. Gastroenterology 130 (7): 2113-2129. doi: